"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

Por Tenenbaum Alexander, Fisman Enrique Z
Publicado em 2010-06-01

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

Por Tenenbaum, Alexander, Fisman, Enrique Z
Publicado em 2004

A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease

Por Fisman, Enrique Z, Tenenbaum, Alexander
Publicado em 2009

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

Por Tenenbaum, Alexander, Fisman, Enrique Z
Publicado em 2010

The ubiquitous interleukin-6: a time for reappraisal

Por Fisman, Enrique Z, Tenenbaum, Alexander
Publicado em 2010

"The metabolic syndrome... is dead": These reports are an exaggeration

Por Tenenbaum, Alexander, Fisman, Enrique Z
Publicado em 2011

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

Por Tenenbaum, Alexander, Fisman, Enrique Z
Publicado em 2012

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Por Tenenbaum, Alexander, Fisman, Enrique Z
Publicado em 2012

Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

Por Fisman, Enrique Z, Tenenbaum, Alexander
Publicado no Cardiovasc Diabetol (2014)

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

Por Fisman, Enrique Z., Tenenbaum, Alexander
Publicado no Cardiovasc Diabetol (2015)

Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?

Por Tenenbaum, Alexander, Fisman, Enrique Z.
Publicado no Cardiovasc Diabetol (2017)

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)

Por Fisman Enrique Z, Tenenbaum Alexander, Motro Michael
Publicado em 2003-03-01

Losartan and diabetic nephropathy: commentaries on the RENAAL study

Por Fisman, Enrique Z, Tenenbaum, Alexander, Motro, Michael
Publicado em 2002

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)

Por Tenenbaum, Alexander, Fisman, Enrique Z, Motro, Michael
Publicado em 2003

Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof

Por Fisman, Enrique Z, Motro, Michael, Tenenbaum, Alexander
Publicado em 2003

Statins research unfinished saga: desirability versus feasibility

Por Fisman, Enrique Z, Adler, Yehuda, Tenenbaum, Alexander
Publicado em 2005

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

Por Tenenbaum, Alexander, Motro, Michael, Fisman, Enrique Z
Publicado em 2005

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor

Por Tenenbaum, Alexander, Klempfner, Robert, Fisman, Enrique Z
Publicado no Cardiovasc Diabetol (2014)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

Por Tenenbaum, Alexander, Fisman, Enrique Z, Motro, Michael, Adler, Yehuda
Publicado em 2006

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease

Por Klempfner, Robert, Leor, Jonathan, Tenenbaum, Alexander, Fisman, Enrique Z, Goldenberg, Ilan
Publicado em 2012